Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider David Shapiro sold 2,000 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $95.00, for a total transaction of $190,000.00. Following the completion of the transaction, the insider now directly owns 41,499 shares in the company, valued at approximately $3,942,405. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
David Shapiro also recently made the following trade(s):
- On Wednesday, April 3rd, David Shapiro sold 562 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $115.01, for a total transaction of $64,635.62.
- On Friday, March 1st, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $103.16, for a total transaction of $206,320.00.
- On Friday, February 15th, David Shapiro sold 2,000 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $111.51, for a total transaction of $223,020.00.
Shares of ICPT opened at $91.70 on Wednesday. The firm has a market cap of $2.74 billion, a price-to-earnings ratio of -8.44 and a beta of 1.63. The company has a debt-to-equity ratio of 19.41, a current ratio of 4.22 and a quick ratio of 4.22. Intercept Pharmaceuticals Inc has a twelve month low of $64.50 and a twelve month high of $133.74.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($2.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.42) by ($0.55). The firm had revenue of $53.30 million for the quarter, compared to analysts’ expectations of $52.53 million. Intercept Pharmaceuticals had a negative net margin of 172.39% and a negative return on equity of 592.58%. The company’s quarterly revenue was up 41.4% on a year-over-year basis. During the same period in the previous year, the company earned ($4.43) EPS. As a group, equities research analysts forecast that Intercept Pharmaceuticals Inc will post -9.13 EPS for the current fiscal year.
A number of equities analysts have recently commented on ICPT shares. Raymond James reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, February 14th. BidaskClub lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 1st. UBS Group started coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, January 23rd. They issued a “buy” rating and a $130.00 price objective for the company. Bank of America reaffirmed an “underperform” rating and issued a $68.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, February 15th. Finally, Wedbush upped their price objective on shares of Intercept Pharmaceuticals from $220.00 to $248.00 and gave the company an “outperform” rating in a research note on Tuesday, February 19th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $144.05.
A number of institutional investors and hedge funds have recently made changes to their positions in ICPT. Eagle Asset Management Inc. purchased a new stake in Intercept Pharmaceuticals during the 4th quarter valued at $28,792,000. Norges Bank purchased a new stake in Intercept Pharmaceuticals during the 4th quarter valued at $28,428,000. Marshall Wace North America L.P. boosted its position in Intercept Pharmaceuticals by 591.0% during the 3rd quarter. Marshall Wace North America L.P. now owns 198,305 shares of the biopharmaceutical company’s stock valued at $25,058,000 after buying an additional 169,606 shares during the period. Two Sigma Investments LP boosted its position in Intercept Pharmaceuticals by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 310,187 shares of the biopharmaceutical company’s stock valued at $31,264,000 after buying an additional 86,171 shares during the period. Finally, Federated Investors Inc. PA boosted its position in Intercept Pharmaceuticals by 1,156.8% during the 3rd quarter. Federated Investors Inc. PA now owns 85,025 shares of the biopharmaceutical company’s stock valued at $10,744,000 after buying an additional 78,260 shares during the period. 70.24% of the stock is owned by institutional investors and hedge funds.
WARNING: “Intercept Pharmaceuticals Inc (ICPT) Insider David Shapiro Sells 2,000 Shares” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2019/04/17/intercept-pharmaceuticals-inc-icpt-insider-david-shapiro-sells-2000-shares.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Recommended Story: What is the Producer Price Index (PPI)?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.